Risk factor

Filtering The Facts: The Urology Care Foundation Spreads Awareness for National Kidney Month

Retrieved on: 
Friday, March 1, 2024
Urination, Diabetes, Fever, Woman, Anemia, Penis, Workplace, Kidney, Blood, Smoking, Mineral, Hormone, Pain, Weight loss, Infection, Rib, Nausea, Vomiting, Human, Kidney cancer, University, Somatic symptom disorder, AUA, Tobacco, Disease, Urine, Risk factor, Low back pain, Risk, American Urological Association, Salt, Water, Phosphorus

BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.

Key Points: 
  • BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.
  • The kidneys also make hormones that help to keep blood pressure stable, make red blood cells and help keep bones strong.
  • Kidney health deserves equal awareness,” said Dr. Timothy Averch, chair of the Urology Care Foundation’s Kidney and Adrenal Health Committee.
  • For National Kidney Month, the Urology Care Foundation is focusing on information about kidney cancer and kidney stones:
    It is estimated that there will be over 81,000 new kidney cancer cases and over 14,000 cancer deaths in the United States in 2024.

Pre-diabetes gets its due: New $1.2 million award aimed at early intervention and treatment

Retrieved on: 
Friday, February 9, 2024
Workforce, Prediabetes, SAN, MD, Blood, Dialysis, Cardiovascular disease, Paratriathlon, Prevalence, Type 2 diabetes, Attention, Diagnosis, University, University of Texas System, Health, Amputation, Diabetes, Risk, Type 2, Kidney, Baptist Health, Endocrinology, Disorder, Eye, Patient, Risk factor, Obesity, Death, Pharmaceutical industry

SAN ANTONIO, Feb. 9, 2024 /PRNewswire-PRWeb/ -- Is your A1C not quite high enough to be diabetes? It still could be serious.

Key Points: 
  • SAN ANTONIO, Feb. 9, 2024 /PRNewswire-PRWeb/ -- Is your A1C not quite high enough to be diabetes?
  • Moreover, the number of people with the condition is expected to double by 2030, with prevalence substantially higher in minority populations, including Hispanics.
  • A combination of lifestyle changes and medication can lead to a long-term prevention of progression to Type 2 diabetes.
  • "Proactive detection and early intervention of pre-diabetes will significantly decrease the progression of diabetes, with a tremendously positive impact in our community," Solis-Herrera said.

Thought Leadership & Innovation Foundation Announces Strategic Partnership with American Macular Degeneration Foundation, Debuts Patient Testimonial Video Featuring TLI Fellow

Retrieved on: 
Monday, February 5, 2024
Research, Women, Seniors, Genetics, Men, Health, Consumer, Optical, Science, Partnership, Public, Macular degeneration, Obesity, AMD, Ageing, Diagnosis, Risk factor, Retina, TLI, Risk, Smoking, Eye, Pharmaceutical industry

Thought Leadership & Innovation Foundation (TLI) , a not-for-profit organization that works at the nexus of science, technology and public health, today announces a strategic partnership with the American Macular Degeneration Foundation (AMDF), beginning with the debut of a patient testimonial video produced by the AMDF and featuring TLI Fellow, Laura Carabello, who documents her timely intervention and management of macular degeneration.

Key Points: 
  • Thought Leadership & Innovation Foundation (TLI) , a not-for-profit organization that works at the nexus of science, technology and public health, today announces a strategic partnership with the American Macular Degeneration Foundation (AMDF), beginning with the debut of a patient testimonial video produced by the AMDF and featuring TLI Fellow, Laura Carabello, who documents her timely intervention and management of macular degeneration.
  • As a patient advocate for AMDF and as Chair of the TLI Fellows, Carabello urges people to understand their risk for macular degeneration, recognize symptoms, seek early treatment and be compliant with ongoing therapy.
  • “Laura's journey provides an insightful and assuring perspective, chronicling her personal challenges with macular degeneration from diagnosis to clinical intervention.
  • Together, TLI and AMDF are dedicated to advancing awareness, research and support, forging a path towards a future where the impact of macular degeneration is minimized, and the gift of sight is preserved.

Urology Care Foundation Spreads Awareness for National Cancer Prevention Month

Retrieved on: 
Wednesday, January 31, 2024
Education, Ache, Penile cancer, Urethral cancer, Urination, Kidney cancer, Bleeding, Fluid mechanics, Testicular cancer, Heredity, Urethra, Radiation, Back pain, Infection, Bladder cancer, Abdomen, Foreskin, Weight loss, FACS, Fever, Groin, Risk factor, Diet, AUA, Blog, Cancer, HPV, Combustion, Woman, Urethral caruncle, Growth, Papillomaviridae, Prostate cancer, Low back pain, Penis, Urethral diverticulum, Rib, Death, Skin, Blood, Disease, AIDS, Risk, Ejaculation, Smoking, Workplace, UTI, American Urological Association, Male, Scrotum, Pain, Tenderness, MBA, Somatic symptom disorder, Urine, Smoker, GCNIS, Ulcer, Birth control

BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.
  • However, there are other urologic cancers that involve the bladder, kidneys and testicles,” said Urology Care Foundation Board of Directors member Brian McNeil, MD, MBA, FACS.
  • The Urology Care Foundation believes the first part of prevention is education.
  • Below are the six main urologic cancers and important resources for each:
    Bladder Cancer is the second most common type of urologic cancer.

UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance

Retrieved on: 
Tuesday, January 30, 2024
EPS, Calendar, Government, Patient, Risk factor, Investment, Balance sheet, NOI, Nasdaq Composite, Dow Jones Industrial Average, EBT, Woman, Cryptocurrency

NI in 4Q 2023 of $4,287 (34.8% of sales) was 5.9% lower than NI of $4,555 (33.6% of sales) in 4Q 2022.

Key Points: 
  • NI in 4Q 2023 of $4,287 (34.8% of sales) was 5.9% lower than NI of $4,555 (33.6% of sales) in 4Q 2022.
  • Despite 15.2% lower Operating Income for the 2023 year, diluted 2023 EPS of $4.574 compared to $4.522 in 2022 were higher by 1.2%.
  • UTMD paid $1,071 ($0.295/share) in dividends to stockholders in 4Q 2023 compared to $1,051 ($0.290/share) paid in 4Q 2022.
  • UTMD paid $4,282 ($1.18/share) in dividends to stockholders in 2023 compared to $3,162 ($0.87/ share) in dividends in 2022.

Henry Schein to Webcast Fourth Quarter and Full-Year 2023 Conference Call and Introduce Its Full-Year 2024 Guidance on Tuesday, February 27, 2024 at 10:00 A.M. ET

Retrieved on: 
Tuesday, January 23, 2024
Medical Supplies, Health, Health Technology, Other Health, Dental, General Health, Senior, Health information management, Coronavirus, Privacy, PPE, Annual report, Collection, Affordable Care Act, Epidemic, Failure, Terrorism, COVID-19 vaccine, Risk factor, Care Act 2014, Public, Sale, Disease, Pandemic, COVID-19, Intellectual property, Security (finance)

The Company will also introduce its earnings expectations for the full-year 2024.

Key Points: 
  • The Company will also introduce its earnings expectations for the full-year 2024.
  • Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer.
  • A replay will be available on the Henry Schein website following the presentation.
  • We undertake no duty and have no obligation to update forward-looking statements except as required by law.

Providence Medical Technology Announces New Publication Demonstrating High Fusion Rates and Successful Outcomes in Previously Failed Cervical Fusion Patients

Retrieved on: 
Thursday, December 7, 2023
Risk factor, Neck, Research, FFS, Orthopedic surgery, Duke University, Borat Subsequent Moviefilm, FUSE, Surgeon, Immobilization, Patient, Journal, ACDF, PCF, Nonunion, Success, Pain, Bleeding, Risk, Journal of Clinical Neuroscience, Hospital, Diabetes, Motion, Smoking, Birth control, Dentistry, Pharmaceutical industry, C7, C3, Neurosurgery

PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- Providence Medical Technology, Inc., a medical device innovator focused on improving surgical outcomes for high-risk spine surgery patients, today announced a new publication in the Journal of Clinical Neuroscience. Dr. Michael M. Haglund and colleagues authored the publication on the long-term outcomes of patients undergoing tissue-sparing Posterior Cervical Fusion (PCF) to revise a 1-level pseudarthrosis following a failed Anterior Cervical Discectomy and Fusion (ACDF).

Key Points: 
  • Dr. Michael M. Haglund and colleagues authored the publication on the long-term outcomes of patients undergoing tissue-sparing Posterior Cervical Fusion (PCF) to revise a 1-level pseudarthrosis following a failed Anterior Cervical Discectomy and Fusion (ACDF).
  • There are over 300,000 cervical fusion procedures performed each year, with over 40% involving patients with some form of risk factors for nonunion.
  • Our tissue-sparing posterior fusion technology is a great option to treat these patients, as is well demonstrated in this study.
  • Providence Medical Technology devices have been used to treat over 20,000 patients and are currently available in over 2,500 hospitals in the United States.

Allstate Reinforces Customer Protection With Redesigned Mobile App

Retrieved on: 
Monday, November 6, 2023
Data Management, Insurance, Technology, Finance, Other Travel, Transportation, Apps, Applications, Other Automotive, Professional Services, Travel, General Automotive, Other Technology, Automotive, Software, Mobile, Wireless, Policy, Weather, Good, Risk factor, App Store (iOS/iPadOS), Wind, Google Wallet, Multimedia, Hotbed, ID, Apple Wallet, GasBuddy, SpotHero, Mobile phone, Cryptocurrency, Online shopping, Allstate

Additional user-focused enhancements in key areas make customer interactions easier, with improved access to ID cards, messages and a redesigned launch screen.

Key Points: 
  • Additional user-focused enhancements in key areas make customer interactions easier, with improved access to ID cards, messages and a redesigned launch screen.
  • “Allstate differentiates itself from the competition by packing an impressive set of features and benefits into one app,” said Antognoli.
  • “In addition to these new tools, Allstate mobile offers customers access to Drivewise and crash detection services, Allstate Roadside Services, and Allstate Identity Protection.
  • And there are additional customer-focused updates to come.”
    Availability to add ID cards to Google Wallet, in addition to Apple Wallet
    Allstate customers can download the Allstate mobile app on the Apple App Store and Android Google Play.

Henry Schein to Webcast Third Quarter 2023 Conference Call and Provide an Update on Its Full-Year 2023 Guidance on Monday, November 13, 2023 at 10:00 a.m. ET

Retrieved on: 
Thursday, November 2, 2023
Medical Devices, Health, Dental, Practice Management, Medical Supplies, Sale, Affordable Care Act, Security (finance), Coronavirus, Terrorism, Health information management, Form 10-K, Care Act 2014, Intellectual property, PPE, Senior, COVID-19 vaccine, Epidemic, COVID-19, Disease, Henry Schein, Risk factor, Privacy, Pandemic, Public, Annual report, Collection, Failure, Pharmaceutical industry

Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer.

Key Points: 
  • Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer.
  • A replay will be available on the Henry Schein website following the presentation.
  • The Company expects to file its Form 10 for the quarterly period ended September 30, 2023, before the end of November 2023.
  • We undertake no duty and have no obligation to update forward-looking statements except as required by law.

Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Tuesday, October 10, 2023
Congress, Neuroscience, BRT, Pharmacokinetics, Idiopathic hypersomnia, Cataplexy, Risk factor, ALKS, Safety, Wakefulness, Risk, Signs and symptoms, Model, OX2R, Investigational New Drug, Diagnosis, Pharmaceutical industry, Alkermes, Narcolepsy, Patient

DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data related to ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy, at World Sleep Congress, taking place Oct. 20-25, 2023, in Rio de Janeiro. In an oral presentation, the company will present initial data from its ongoing phase 1 study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia. This presentation will include initial clinical proof-of-concept data from the first cohort of four patients with narcolepsy type 1.

Key Points: 
  • — Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orexin 2 Receptor Agonist —
    DUBLIN, Oct. 10, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data related to ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy, at World Sleep Congress, taking place Oct. 20-25, 2023, in Rio de Janeiro.
  • In an oral presentation, the company will present initial data from its ongoing phase 1 study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia.
  • This presentation will include initial clinical proof-of-concept data from the first cohort of four patients with narcolepsy type 1.
  • We look forward to presenting data at the World Sleep Congress, including our first clinical data for ALKS 2680 in patients with narcolepsy."